Is there any place for resistant starch, as alimentary prebiotic, for patients with type 2 diabetes?

Complementary Therapies in Medicine

Volumn 23, Issue 6, 2015, Pages 810-815

  Gargari, Bahram Pourghassem ^a   Namazi, Nazli ^b   Khalili, Mohammad ^c   Sarmadi, Bahareh ^d   Jafarabadi, Mohammad Asghari ^a   Dehghan, Parvin ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Inflammation; Lipid profile; Resistant starch; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; METFORMIN; PLACEBO; RESISTANT STARCH; STARCH; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PREBIOTIC AGENT;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; TRIACYLGLYCEROL BLOOD LEVEL; AGED; ANALYSIS; DIET THERAPY; IRAN; MIDDLE AGED;

ADULT; AGED; BLOOD GLUCOSE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION; IRAN; MIDDLE AGED; PREBIOTICS;

EID: 84949670561     PISSN: 09652299     EISSN: 18736963     Source Type: Journal    
DOI: 10.1016/j.ctim.2015.09.005     Document Type: Article

References (28)

1. Garcia C., Feve B., Ferre P. Diabetes and inflammation: fundamental aspects and clinical implications. Diabetes Metabol 2010, 36(5):327-338.
2. Aliasgharzadeh A., Dehghan P., Pourghassem Gargari B., Asghari-Jafarabadi M. Resistant dextrin, as a prebiotic, improves insulin resistance and inflammation in women with type 2 diabetes: a randomized controlled clinical trial. Br J Nutr 2015, 113:321-330.
3. Li, L. Assessing prebiotic effects of resistant starch on modulating gut microbiota with an in vivo animal model and an in vitro semi-continuous fermentation model. 2010. Graduate Theses and Dissertations. Paper 11655.
4. Homayouni A., Amini A., Khodavirdivand A. Resistant starch in food industry: a changing outlook for consumer and producer. Starch 2014, 66(1-2):102-114.
5. Lecerf J.M.D., Epeint F., Clerc E. Xylo-oligosaccharide (XOS) in combination with inulin modulates both the intestinal environment and immune status in healthy subjects, while XOS alone only shows prebiotic properties. Br J Nutr 2012, 108. 1847-58.5.
6. Moore, S. A. Studies on mechanisms of resistant starch analytical methods. 2013. Graduate Theses and Dissertations. Paper 13568.
7. Topping D.L., Clifton P.M. Short-chain fatty acids and human colonic function: roles of resistant starch and non starch polysaccharides. Physiol Rev 2001, 81(3):1031-1064.
8. Le Leu R.K., Hu Y., Brown I.L., Young G.P. Effect of high amylose maize starches on colonic fermentation and apoptotic response to DNA-damage in the colon of rats. Nutr Metab (Lond) 2009, 6:11.
9. Arpaia N., Rudensky A.Y. Microbial metabolites controls gut inflammatory responses. Proc Natl Acad Sci 2014, 111(6):2058-2059.
10. Keshani P., Farvid M. Understanding the effective factors on high-fiber food consumption from the viewpoint of type 2 diabetic patients: a qualitative study. Iran J Nutr Sci Food Technol 2011, 7:11-22.
11. Behall K.M., Scholfield D.J., Hallfrisch J.G. Consumption of both resistant starch and glucan improves postprandial plasma glucose and insulin in women. Diabetes Care 2006, 29(5):976-981.
12. Johnston K.L., Thomas E.L., Bell J.D. Resistant starch improves insulin sensitivity in metabolic syndrome. Diabetic Med 2010, 27(4):391-397.
13. Maki K.C., Pelkman C.L., Finocchiaro E.T. Resistant starch from high-amylose maize increases insulin sensitivity in overweight and obese men. J Nutr 2012, 142(4):717-723.
14. Nilsson A.C., Astman E.M., Knudsen K.E.B. A cereal-based evening meal rich in indigestible carbohydrates increases plasma butyrate the next morning. J Nutr 2010, 140(11):1932-1936.
15. Nilsson A.C., Astman E.M., Holst J.J. Including indigestible carbohydrates in the evening meal of healthy subjects improves glucose tolerance, lowers inflammatory markers, and increases satiety after a subsequent standardized breakfast. J Nutr 2008, 138(4):732-739.
16. Mitra A., Bhattacharya D., Roy S. Role of resistant starches particularly rice containing resistant starches in type 2 diabetes. J. Human Ecol. 2007, 21(1):47-51.
17. Penn-Marshall M., Holtzman G.I., Barbeau W.E. African Americans may have to consume more than 12g a day of resistant starch to lower their risk for type 2 diabetes. J Med Food 2010, 13(4):999-1004.
18. Pocock S.J. Clinical Trials: A Practical Approach 1990, 128. John Wiley & Sons, Chichester, NY.
19. Dehghan P., PourghassemGargari B., Asgharijafar-abadi M. Oligofructose-enriched inulin improves some inflammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized controlled clinical trial. Nutrition 2014, 30(4):418-423.
20. Dehghan P., PourghasemGargari B., AsghariJafar-Abadi M. Inulin controls inflammation and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized-controlled clinical trial. Int J Food Sci Nutr 2014, 65(1):117-123.
21. Dehghan P., PourghassemGargari B., Asgharijafar-abadi M. Effects of high performance inulin supplementation on glycemic status and lipid profile in women with type 2 diabetes: a randomized, placebo-controlled clinical trial. Health Promot Perspect 2013, 3(1):55-63.
22. Pourghassem Gargari B., Dehghan P., Aliasgharzadeh A. Effects of high performance inulin supplementation on glycemic control and antioxidant status in women with type 2 diabetes. Diabetes Metab J 2013, 37(2):140-148.
23. Bodinham C.L., Smith L., Thomas E.L. Efficacy of increased resistant starch consumption in human type 2 diabetes. Endocrine Connect 2014, 3(2):75-84.
24. Segain J.P., De La Blatiere D.R., Bourreille A. Butyrate inhibits inflammatory responses through NFK-B inhibition: implications for Crohn's disease. Gut 2000, 47(3):397-403.
25. Zhang H., Reilly M.P. The anti-inflammatory effects of HDL through ATF3: benefit beyond cholesterol transport-dependent processes. Arterioscler Thromb Vasc Biol 2014, 34(6):e11.
26. Castillo J., Aparicio-Traipala M., Francisco-Luria M. Effects of native banana starch supplementation on body weight and insulin sensitivity in obese type 2 diabetics. Int J Environ Res Publ Health 2010, 7(5):1953-1962.
27. Aziz A.A., Kenney L.S., Goulet B. Dietary starch type affects body weight and glycemic control in freely fed but not energy-restricted obese rats. J Nutr 2009, 139(10):1881-1889.
28. Diamant M., Blaak E.E., De Vos W.M. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes?. Obes Rev 2011, 12(4):272-281.